Provided by Tiger Trade Technology Pte. Ltd.

Galmed Pharmaceuticals

4.12
+0.19404.94%
Post-market: 4.06-0.0590-1.43%17:02 EDT
Volume:14.70K
Turnover:60.08K
Market Cap:4.29M
PE:-0.26
High:4.22
Open:3.97
Low:3.94
Close:3.93
52wk High:13.20
52wk Low:3.29
Shares:1.04M
Float Shares:1.01M
Volume Ratio:1.55
T/O Rate:1.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-16.1401
EPS(LYR):-19.1292
ROE:-72.12%
ROA:-33.45%
PB:0.31
PE(LYR):-0.22

Loading ...

Galmed Announces Results From First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (Am); 400Mg Am Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (Aa) 300Mg

THOMSON REUTERS
·
May 14

Galmed Pharmaceuticals Partners with Tissue Dynamics on Human Cardiac Fibrosis Platform

TIPRANKS
·
May 06

Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics

THOMSON REUTERS
·
May 06

Galmed partners Tissue Dynamics to develop chronic cardiac fibrosis organoid platform

Reuters
·
May 06

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Galmed Pharmaceuticals (GLMD), Neurocrine (NBIX) and Mesoblast (MESO)

TIPRANKS
·
Apr 15

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Nano-X, Travere

Reuters
·
Apr 14

Galmed Pharmaceuticals Teams with Tel Aviv University on Aramchol for Metastatic Brain Cancer

TIPRANKS
·
Apr 14

Galmed partners with Tel Aviv University to test Aramchol in brain metastases

Reuters
·
Apr 14

Galmed Announces a Collaboration Agreement With Tel Aviv University to Evaluate Its Scd1 Inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers

THOMSON REUTERS
·
Apr 14

BUZZ-U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman

Reuters
·
Apr 10

Why Is Galmed Pharmaceuticals Stock (GLMD) Up Today?

TIPRANKS
·
Apr 09

BUZZ-Galmed jumps on lab data on new brain-penetrating version of experimental drug

Reuters
·
Apr 09

Galmed Pharmaceuticals Ltd - Develops Brain-Penetrating Formulation of Aramchol With Barcode Nanotech

THOMSON REUTERS
·
Apr 09

Galmed plans Phase 1b/2 Parkinson’s trial for brain-penetrating Aramchol in H2 2026

Reuters
·
Apr 09

Galmed net loss widens 37% to $10 million in FY25

Reuters
·
Apr 01

Galmed Pharmaceuticals Ltd expected to post a loss of 51 cents a share - Earnings Preview

Reuters
·
Mar 27

Galmed Pharmaceuticals Ltd. CFO Doron Leib Cohen files initial beneficial ownership statement

Reuters
·
Mar 18

Galmed Pharmaceuticals COO Nehemya Guy files initial beneficial ownership statement

Reuters
·
Mar 18

Galmed Pharmaceuticals names Chief Accounting Officer Yohai Stenzler in initial beneficial ownership filing

Reuters
·
Mar 18

Galmed Pharmaceuticals Director Carol L. Brosgart Files Initial Beneficial Ownership Statement

Reuters
·
Mar 18